Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001437749-26-004912

Chief Scientific Officer sold 100 shares at $16.00 ($1,600)

  • Chief Scientific Officer acquired 100 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lorrain Daniel S. · Chief Scientific Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-19 Exercise or conversion : show line 1 in the form 10b5-1 +100 $1.01 $101 156,152 D
2026-02-19 Sale : show line 2 in the form 10b5-1 −100 $16.00 $1,600 156,052 D
Open-market sales · 100 sh · avg $16.00 · $1,600

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-02-19 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −100 75,430 D
Loading xslF345X05/rdgdoc.xml…